InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery
February 19, 2024 02:00 ET
|
InveniAI LLC
Teams will work together by leveraging InveniAI's technology platform to identify, evaluate, and optimize novel targets across Ono’s diseases of interestOno will access InveniAI’s AI platform...
AI Drug Discovery Company Insilico Medicine Offers Free Course on Target Identification
May 10, 2023 09:00 ET
|
InSilico Medicine
New York, May 10, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced today that it is releasing a course on Disease...
InveniAI's AlphaMeld Platform Debuts the Addition of ChatAlphaMeld™, A Powerful Tool Designed to Scale Target and Drug Discovery and Development
April 04, 2023 08:43 ET
|
InveniAI LLC
Powered by GPT-4, ChatAlphaMeld enables user interaction across functional stakeholders to automate hypothesis generation and prioritization Integrated into the AlphaMeld workflow, ChatAlphaMeld is...
Insilico Medicine launches 6th generation Intelligent Robotics Lab to further accelerate its AI-driven drug discovery
January 05, 2023 09:00 ET
|
InSilico Medicine
New York, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical stage, end-to-end artificial intelligence (AI)-driven drug discovery company, held the launch ceremony for Life...
Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases and cancer using AI
December 01, 2022 09:00 ET
|
InSilico Medicine
New York, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, and the University of Copenhagen announced...
InveniAI and Kyowa Kirin Announce Achievement of Milestone in Research Collaboration
May 31, 2022 08:15 ET
|
InveniAI LLC
GUILFORD, Conn. and TOKYO, May 31, 2022 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug and target discovery...
InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas
December 16, 2021 08:10 ET
|
InveniAI LLC
Collaboration enables Kyowa Kirin's R&D team to access InveniAI's data-driven discovery platform in expanded therapeutic areasInveniAI's AlphaMeld® platform to provide unique Translational Edge...
Sosei Heptares and InveniAI Enter a Multi-Target AI-Powered and GPCR-Focused Drug Discovery Collaboration
July 06, 2021 08:10 ET
|
InveniAI LLC
Collaboration to create transformative therapeutics for immune diseases by combining InveniAI's validated AI-based platform, AlphaMeld®, with Sosei Heptares' GPCR Structure-based Drug Design and early...
InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis
May 11, 2021 08:10 ET
|
InveniAI LLC
Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseasesDr. Alesci’s...
InveniAI and Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaboration
April 27, 2021 08:10 ET
|
InveniAI LLC
Teams will work together by leveraging InveniAI's technology to identify, evaluate, and optimize novel targets for drug discoveryShionogi will synthesize and develop compounds for targets identified...